Younger patients who received certain chemotherapies for solid tumors or leukemia may not have T-cells capable of becoming effective CAR T-cells. READ MORE
A recent study found that a biosimilar provides improved outcomes without increased risk of toxicity for patients with DLBCL and treatment-induced neutropenia.
The ICER has released a scoping document that will compare the clinical effectiveness and value of multiple CAR-T cell treatments under review by the FDA.
The US Food and Drug Administration has approved the second CAR T-cell therapy, indicated for certain types of non-Hodgkin lymphoma.
The US Food and Drug Administration (FDA) has made the first gene therapy available, marking their approval of a new approach to the treatment of cancer.